利奈唑胺 (PNU-100766) 是恶唑烷酮类合成抗生素中的第一个成员｜ MedChemExpress (MCE)

最新推荐文章于 2024-08-02 09:29:13 发布

MedChemExpress (MCE)

最新推荐文章于 2024-08-02 09:29:13 发布

阅读量284

点赞数 4

文章标签：抑制剂 MCE

本文链接：https://blog.csdn.net/mmmm12134/article/details/138997903

版权

Linezolid

中文名：利奈唑胺

CAS：165800-03-3

品牌：MedChemExpress (MCE)

存储条件：4°C, protect from light

生物活性：利奈唑胺 (PNU-100766) 是恶唑烷酮类合成抗生素中的第一个成员。利奈唑胺通过抑制细菌蛋白质合成的启动起作用。利奈唑胺用于治疗由对其他几种抗生素耐药的革兰氏阳性菌引起的严重感染[1][2][3]。

[1]. Clemett D, Markham A. Linezolid. Drugs. 2000 Apr;59(4):815-27; discussion 828.[2]. Chiappini E, Conti C, Galli L et al. Clinical efficacy and tolerability of linezolid in pediatric patients: a systematic review. Clin Ther. 2010 Jan;32(1):66-88.[3]. Perry CM, Jarvis B. Linezolid: a review of its use in the management of serious gram-positive infections. Drugs. 2001;61(4):525-51.[4]. He MZ, Jiang YW, Cai C. Mechanisms and epidemiology of linezolid resistance in staphylococci.Zhonghua Jie He He Hu Xi Za Zhi. 2012 May;35(5):360-2.[5]. Karau MJ, Tilahun AY, Schmidt SM, Clark CR, Patel R, Rajagopalan G. Linezolid is Superior to Vancomycin in Experimental Pneumonia Caused by Superantigen-Producing Staphylococcus aureus in HLA class II Transgenic Mice. Antimicrob Agents Chemother. 2012 Jul 30.